Your browser doesn't support javascript.
loading
Haemodynamic effects of the flavonoid quercetin in rats revisited.
Vrolijk, Misha F; van Essen, Helma; Opperhuizen, Antoon; Bast, Aalt; Janssen, Ben J.
Afiliación
  • Vrolijk MF; Department of Pharmacology & Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • van Essen H; Faculty of Science and Engineering, Maastricht University Campus Venlo, Venlo, The Netherlands.
  • Opperhuizen A; Department of Pharmacology & Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • Bast A; Department of Pharmacology & Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • Janssen BJ; Office for Risk Assessment andResearch (BuRO), Netherlands Food and Consumer Product Safety Authority (NVWA), Utrecht, The Netherlands.
Br J Pharmacol ; 177(8): 1841-1852, 2020 04.
Article en En | MEDLINE | ID: mdl-31877232
ABSTRACT
BACKGROUND AND

PURPOSE:

The flavonoid quercetin increased the in vitro potency of the α1 -antagonist tamsulosin to reduce phenylephrine-dependent arterial contractions by 10-fold. To examine if this supplement-drug interaction luxates hypotensive and orthostatic events in vivo, several set of studies were conducted in spontaneously hypertensive (SHR) and normotensive (Wistar Kyoto [WKY]) rats. EXPERIMENTAL

APPROACH:

First, in rats pretreated with quercetin or its vehicle, responses to phenylephrine and tamsulosin were examined. Second, tamsulosin-induced changes in renal, mesenteric, hindquarter and carotid conductance were compared in quercetin- and vehicle-treated rats instrumented with Doppler flow probes. Animals were also placed on a tilt table to record regional haemodynamic changes to orthostatic challenges. Third, adult SHR were instrumented with telemeters to measure 24-hr patterns of BP. Recordings were made before and during a 5-week oral treatment of quercetin. Finally, pre-hypertensive SHR were treated with quercetin from 4 to 8 weeks of age and arterial pressure was measured at 8 and 12 weeks. KEY

RESULTS:

Pretreatment with quercetin did not influence the responses to phenylephrine and tamsulosin, in neither WKY nor SHR. While tamsulosin treatment and tilting lowered BP and increased conductance in all vascular beds, effect size was not influenced by pretreatment with quercetin. Prolonged treatment with quercetin, in either prehypertensive SHR or adult SHR with established hypertension did not lower BP. CONCLUSIONS AND IMPLICATIONS Cumulatively, these data demonstrate that quercetin does not amplify haemodynamic effects of tamsulosin or tilting in vivo in rats and has no effect on BP development in SHR.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Quercetina / Hipertensión Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Quercetina / Hipertensión Límite: Animals Idioma: En Revista: Br J Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos